Barati Sama, Ghoflchi Sahar, Hosseinzadeh Pejman, Pouramini Sobhan, Hosseini Hossein, Jalili-Nik Mohammad
Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Cancer Med. 2025 Sep;14(18):e71187. doi: 10.1002/cam4.71187.
Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis and low survival rates. Standard treatments, such as surgery and radiotherapy, are limited by tumor infiltration and resistance. To review current vaccine strategies for GBM, including peptide, virotherapy, cell-based, and genetic vaccines, with a focus on mRNA vaccines.
Relevant literature on GBM vaccines and immunotherapy was reviewed to summarize design, mechanisms, and potential clinical applications.
Cancer vaccines aim to activate the immune system to target tumor cells. mRNA vaccines are promising due to their flexibility, rapid production, and strong immune activation, though clinical investigation is ongoing.
Vaccine-based therapies, particularly mRNA vaccines, hold potential for personalized GBM treatment, but further studies are needed to confirm efficacy and optimize use.
胶质母细胞瘤(GBM)是一种侵袭性原发性脑肿瘤,预后差,生存率低。手术和放疗等标准治疗方法受到肿瘤浸润和耐药性的限制。旨在综述当前针对GBM的疫苗策略,包括肽疫苗、病毒疗法、细胞疫苗和基因疫苗,重点关注mRNA疫苗。
对有关GBM疫苗和免疫疗法的相关文献进行综述,以总结其设计、机制和潜在的临床应用。
癌症疫苗旨在激活免疫系统以靶向肿瘤细胞。mRNA疫苗因其灵活性、快速生产和强大的免疫激活能力而具有前景,尽管临床研究仍在进行中。
基于疫苗的疗法,尤其是mRNA疫苗,在个性化GBM治疗方面具有潜力,但需要进一步研究以确认疗效并优化使用。